NCT03418493View on ClinicalTrials.gov

A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 30, 2018

Primary Completion Date

December 24, 2018

Study Completion Date

July 29, 2019

Conditions
Psoriasis
Interventions
DRUG

LY3316531 - IV

Administered IV.

DRUG

LY3316531 - SC

Administered SC.

DRUG

Placebo - IV

Administered IV.

Trial Locations (2)

21225

PAREXEL-Phase 1 Baltimore Harbor Hospital Center, Baltimore

91206-4140

Parexel Early Phase Unit at Glendale, Glendale

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03418493 - A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis | Biotech Hunter | Biotech Hunter